Oramed Pharmaceuticals Inc. filed a Form 8-K on November 19, 2026, disclosing the resolution of a Delaware stockholder class action challenging provisions of the company's bylaws governing stockholder action by written consent.

Key Highlights

  • Lawsuit filed: A purported stockholder filed a putative class action on February 20, 2026, in the Court of Chancery of the State of Delaware, captioned Agnes Lotz v. Oramed Pharmaceuticals Inc., C.A. No. 2026-0244-PAF.
  • Allegation: The Action challenged provisions of Article III, Section 11 of the company's bylaws, alleging they violated Sections 213(b) and 228(a) of the Delaware General Corporation Law.
  • Bylaw amendment: The company amended its bylaws on June 28, 2026, mooting the Action.
  • Dismissal: On July 2, 2026, the Court entered an order dismissing the Action, retaining jurisdiction solely to resolve any application by plaintiff's counsel for attorneys' fees and expenses.
  • Settlement payment: Without admitting fault or wrongdoing, the company agreed to pay plaintiff's counsel $125,000 in attorneys' fees and expenses.
  • Company position: The company denies that the challenged bylaw provisions violated the DGCL.

Oramed Resolves Delaware Bylaw Challenge With Bylaw Amendment and Fee Payment

According to the filing, a purported stockholder identified as Agnes Lotz filed a putative class action on February 20, 2026, in the Court of Chancery of the State of Delaware. The complaint targeted Article III, Section 11 of Oramed's bylaws, specifically the provisions governing stockholder action by written consent, alleging those provisions violated Sections 213(b) and 228(a) of the Delaware General Corporation Law.

The company disclosed that it "denies that the challenged provisions of its bylaws violated the DGCL," but stated it "agreed to amend its bylaws to avoid the distraction and cost of needless litigation." The bylaw amendment took effect on June 28, 2026, which the filing states mooted the Action. The Court of Chancery subsequently entered an order on July 2, 2026, dismissing the Action while retaining jurisdiction solely to resolve any application by plaintiff's counsel for attorneys' fees and expenses.

The filing further states that, without admitting fault or wrongdoing, Oramed agreed to pay plaintiff's counsel $125,000 in attorneys' fees and expenses in connection with the mooted claims. The 8-K was signed by Nadav Kidron, President and CEO, on behalf of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). The common stock carries a par value of $0.012 and is listed on both the Nasdaq Capital Market and the Tel Aviv Stock Exchange.

What Was Disclosed

Oramed Pharmaceuticals disclosed the filing, resolution, and dismissal of a Delaware stockholder class action challenging its bylaw provisions, the amendment of those bylaws on June 28, 2026, and an agreed payment of $125,000 in attorneys' fees and expenses to plaintiff's counsel.